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Clinical PerspectiveWhat Is New?This multicenter Japanese registry demonstrated that a subsequent acute coronary syndrome after the index percutaneous coronary intervention was associated with higher mortality.However, his association was less apparent after a subsequent unplanned coronary revascularization or an unstable angina event.What Are the Clinical Implications?Whereas acute coronary syndrome readmissions seem to be an important component of clinical end points, the roles of unplanned revascularization or unstable angina alone as components of clinical trial end points need to be cautiously interpreted.Given the limited prognostic benefit from subsequent revascularization after the index percutaneous coronary intervention, the incremental value of performing routine angiographic assessment should be revisited.

Introduction {#jah32617-sec-0008}
============

Composite end points have been widely used in contemporary clinical trials for acquiring sufficient statistical power to detect the difference in outcomes between groups.[1](#jah32617-bib-0001){ref-type="ref"}, [2](#jah32617-bib-0002){ref-type="ref"} In the field of ischemic heart disease, many trials examine the impact of therapy on combined clinical outcomes, including cardiovascular death, myocardial infarction (MI), stroke, unstable angina (UA) admissions, and revascularization procedures.[3](#jah32617-bib-0003){ref-type="ref"}, [4](#jah32617-bib-0004){ref-type="ref"}, [5](#jah32617-bib-0005){ref-type="ref"}, [6](#jah32617-bib-0006){ref-type="ref"}, [7](#jah32617-bib-0007){ref-type="ref"} Although the clinical impact of the first 3 events are of uncontested importance, it remains unclear whether nonfatal events, such as UA and coronary revascularizations, are individually associated with subsequent survival and warrant inclusion as a component of major adverse cardiovascular events (MACE). For example, in trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting for multivessel coronary artery disease, many demonstrate that the use of coronary artery bypass grafting, as compared with PCI, results in lower rates of MACE, mainly attributed to a higher rate of repeat revascularization with PCI. Given that these studies typically show no differences in hard end points (eg, mortality), but may be of insufficient duration for the full mortality benefit to be realized, more data on the long‐term prognostic significance of different MACE components are needed.[5](#jah32617-bib-0005){ref-type="ref"}, [6](#jah32617-bib-0006){ref-type="ref"}, [7](#jah32617-bib-0007){ref-type="ref"}

To better illuminate the prognostic importance of individual MACE components---including admissions for acute coronary syndromes (ACS) and unplanned coronary revascularizations---that often comprise composite end points in clinical trials of coronary artery disease, this study sought to evaluate the association of ACS admission and unplanned coronary revascularization with 2‐year survival in 2 separate propensity‐matched cohorts of patients who did and did not experience these clinical events from a contemporary large, regional Japanese PCI population.

Methods {#jah32617-sec-0009}
=======

Study Population {#jah32617-sec-0010}
----------------

Data from the JCD‐KiCS (Japan Cardiovascular Database Keio interhospital Cardiovascular Studies) were used to address our aims. JCD‐KiCS is a prospective, multicenter registry designed to collect clinical variables and outcomes data on consecutive patients undergoing PCI for both acute and nonacute indications using dedicated clinical research coordinators at each site.[8](#jah32617-bib-0008){ref-type="ref"}, [9](#jah32617-bib-0009){ref-type="ref"}, [10](#jah32617-bib-0010){ref-type="ref"}, [11](#jah32617-bib-0011){ref-type="ref"}, [12](#jah32617-bib-0012){ref-type="ref"}, [13](#jah32617-bib-0013){ref-type="ref"}, [14](#jah32617-bib-0014){ref-type="ref"} The clinical variables and in‐hospital outcomes for the JCD‐KiCS were aligned with the data elements of the National Cardiovascular Data Registry CathPCI Registry v4.1.[15](#jah32617-bib-0015){ref-type="ref"}, [16](#jah32617-bib-0016){ref-type="ref"} The participating hospitals in Kanto, Japan (Tokyo, Tochigi, Saitama, Chiba, and Kanagawa Prefecture) were mostly large tertiary care referral centers (more than 200 beds; N=12), but included a few mid‐sized satellite hospitals (less than 200 beds; N=3). Trained data coordinators at participating hospitals consecutively recorded and registered hospital visits for PCI using an internet‐based data collection infrastructure. This process was overseen by a senior study coordinator (Dr I.U.), and quality of the reporting was verified through on‐site audits by the principal investigators (Drs S.K. and H.M.). This study was approved by each participating hospital\'s ethics review board, and written informed consent was obtained from each patient.

For the present report, JCD‐KiCS data (4179 patients; January 1, 2009 to December 31, 2011) were analyzed. Staged PCI procedures were excluded from the present analysis (n=237 patients). Follow‐up data were obtained from hospital charts or by contacting patients or referring physicians through mail or telephone. Relatively complete follow‐up (84.9%) was obtained, with a total of 594 patients (15.1%) being excluded because of loss to follow‐up (mean follow‐up duration, 665±147 days). In comparison with those completing at least 1‐year follow‐up (Table [1](#jah32617-tbl-0001){ref-type="table-wrap"}), those who were lost to follow‐up had higher rates of past MI, PCI, or hemodialysis, but presented with less clinically significant manifestations. They often were more asymptomatic patients and less likely to present with an ACS. After these exclusions, 3348 patients were included in the study (Figure [1](#jah32617-fig-0001){ref-type="fig"}).

###### 

Differences in Characteristics Between Patients With and Without at Least 1‐Year Follow‐up

  Characteristic                                Total         Missing      *P* Value     
  --------------------------------------------- ------------- ------------ ------------- ---------
  Demographics                                                                           
  Male, n (%)                                   3159 (80.1)   489 (82.3)   2670 (79.7)   0.147
  Age, y                                        67.5±10.9     67.5±11.7    67.5±10.7     0.977
  BMI                                           24.2±3.6      23.9±3.8     24.3±3.6      0.034
  Clinical factors (%)                                                                   
  Smoking                                       1406 (35.7)   213 (35.9)   1193 (35.6)   0.043
  Family history of CAD                         569 (14.4)    75 (12.6)    494 (14.8)    0.037
  Hypertension                                  2811 (71.3)   441 (74.2)   2370 (70.8)   0.086
  Hypercholesterolemia                          2532 (64.2)   375 (63.1)   2157 (64.4)   0.544
  Diabetes mellitus                             1624 (41.2)   267 (44.9)   1357 (40.5)   0.047
  Renal dysfunction                             702 (17.8)    141 (23.7)   561 (16.8)    \<0.001
  Past history of MI                            826 (21.0)    195 (32.8)   631 (18.8)    \<0.001
  Past history of HF                            307 (7.8)     59 (9.9)     248 (7.4)     0.098
  Past PCI                                      1099 (27.9)   329 (55.4)   770 (23.0)    \<0.001
  Past CABG                                     216 (5.5)     31 (5.2)     185 (5.5)     0.762
  Hemodialysis                                  164 (4.2)     46 (7.7)     118 (3.5)     \<0.001
  Cerebrovascular disease                       337 (8.5)     53 (8.9)     284 (8.5)     0.724
  Peripheral arterial disease                   290 (7.4)     49 (8.2)     241 (7.2)     0.366
  Chronic lung disease                          119 (3.0)     24 (4.0)     95 (2.8)      0.264
  Presentation (%)                                                                       
  STEMI                                         1068 (27.1)   148 (24.9)   920 (27.5)    \<0.001
  UA/NSTEMI                                     1065 (27.0)   120 (20.2)   945 (28.2)    
  Stable angina                                 1175 (29.8)   185 (31.1)   990 (29.6)    
  Silent ischemia                               584 (14.8)    128 (21.5)   456 (13.6)    
  Other                                         47 (1.2)      11 (1.9)     36 (1.1)      
  Angina (applied only to elective cases) (%)                                            
  No symptoms                                   656 (37.3)    138 (44.1)   518 (35.8)    0.003
  CCS class                                                                              
  I                                             304 (7.7)     46 (14.7)    213 (14.7)    
  II                                            596 (33.9)    96 (30.7)    500 (34.6)    
  III                                           166 (9.4)     13 (4.2)     153 (10.6)    
  IV                                            23 (1.3)      6 (1.9)      17 (1.2)      
  Unknown                                       59 (3.4)      14 (4.5)     45 (3.1)      

All values are expressed as the mean±SD or as a number with the percentage of subjects in parentheses. BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS class, Canadian Cardiovascular Society angina class; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐elevation myocardial infarction; UA/NSTEMI, unstable angina/non‐ST‐elevation myocardial infarction.

![Flow chart of the study population. ACS indicates acute coronary syndrome; f/u, follow‐up; PCI, percutaneous coronary intervention.](JAH3-6-e006529-g001){#jah32617-fig-0001}

Definitions {#jah32617-sec-0011}
-----------

The standard National Cardiovascular Data Registry CathPCI data definitions were used in JCS‐KiCS.[17](#jah32617-bib-0017){ref-type="ref"} The principal outcome measure for this analysis was all‐cause death. ACS was defined as admission to a hospital for a primary diagnosis of UA or acute MI. Unplanned revascularization was defined as the first future revascularization after the index procedure. Staged PCI procedures were defined as PCI procedures that were performed during the same hospitalization of the index procedure or within 30 days after the index procedure in a setting other than ACS.

Statistical Analysis {#jah32617-sec-0012}
--------------------

All data are expressed as mean±SD for continuous variables and percentages for categorical variables. Differences in each variable between groups were evaluated using Student unpaired *t* test for continuous variables and chi‐square or Fisher\'s exact tests for categorical variables.

First, we compared patients\' characteristics by the presence or absence of subsequent ACS admission, and by the presence or absence of unplanned coronary revascularization. Then, we created 2 separate matched cohorts for each of the events (subsequent ACS admission or subsequent coronary revascularization) using the same methodology. In order to account for differences in characteristics between the 2 groups (patients with ACS rehospitalization versus those without ACS rehospitalization, or patients with subsequent revascularization versus those without subsequent revascularization), we derived propensity scores to assess the probability of each event, by constructing nonparsimonious multivariable logistic regression models. In the propensity score model, the occurrence of each event was used as the dependent variable, and baseline characteristics were entered as covariates (age, sex, body mass index, previous history \[diabetes mellitus, renal dysfunction, chronic obstructive pulmonary disease, MI, heart failure, peripheral artery disease, hypertension, hyperlipidemia, cerebrovascular disease, coronary artery disease, PCI, and coronary artery bypass grafting\], presentation on admission \[ST‐elevation MI, shocked status, heart failure, and Canadian Cardiovascular Society \>2\], medication on admission \[aspirin, clopidogrel, and beta‐blocker\], and laboratory data \[postprocedural creatine kinase‐MB\]).

We then matched patients who had subsequent ACS admission or coronary revascularization to those without subsequent ACS admission or coronary revascularization using greedy matching on the logit of the propensity score (1:1). The caliper width was chosen as 0.2 times the pooled SD of the logit propensity scores for the groups. Balance between the groups was assessed by calculating the standardized differences, where \<0.10 was considered to indicate good balance between the groups. Following the propensity matching, in order to assess the association of subsequent ACS admission or coronary revascularization on long‐term mortality, in each matched data set, the starting time was set to the time to the occurrence of each event for calculating the time to death or censoring. Finally, a Cox proportional hazards model for long‐term mortality was stratified and weighted by matched sets with weighted K‐M curves. Similar analysis was performed for coronary revascularization admissions. Finally, because UA is less severe than acute MI, we also generated a separate propensity‐matched cohort for this post‐PCI event.

Analyses of data were performed using SAS (version 9.1; SAS institute Inc, Cary, NC) and SPSS software (version 22; SPSS, Inc, Chicago, IL). All *P* values were 2‐sided, and significance was defined as *P*\<0.05 for all analyses.

Results {#jah32617-sec-0013}
=======

The cohort (Table [2](#jah32617-tbl-0002){ref-type="table-wrap"}) had a mean age of 67.5±10.7 years; 79.7% were male. When compared with patients without a future ACS event, those with a future ACS event were older and had a higher prevalence of renal dysfunction. Past histories of MI, heart failure, PCI, and coronary artery bypass grafting were also more frequently observed in patients with a subsequent ACS event than those without. Moreover, in patients with a future ACS event, coronary intervention had been more commonly performed for UA and non‐ST‐elevation MI. In contrast, baseline characteristics of patients with and without a future revascularization were not significantly different.

###### 

Baseline Characteristics in Study Cohort

  Characteristic                                Total             Future ACS      *P* Value         Future Revascularization   *P* Value                         
  --------------------------------------------- ----------------- --------------- ----------------- -------------------------- --------------- ----------------- -------
  Demographics (%)                                                                                                                                               
  Male                                          2670 (79.7)       169 (79.0)      2501 (79.8)       0.77                       164 (82.8)      2506 (79.6)       0.266
  Age, y                                        67.5±10.7         69.2±10.3       67.4±10.7         0.018                      67.8±9.4        67.5±10.8         0.692
  BMI                                           24.3±3.6          24.0±3.4        24.3±3.6          0.171                      24.4±3.7        24.3±3.6          0.575
  Clinical factors (%)                                                                                                                                           
  Smoking                                       1193 (35.6)       78 (36.4)       1115 (35.6)       0.905                      65 (32.8)       1128 (35.8)       0.651
  Family history of CAD                         494 (14.7)        36 (16.8)       458 (14.6)        0.651                      29 (14.6)       465 (14.8)        0.312
  Hypertension                                  2370 (70.8)       154 (72.0)      2216 (70.7)       0.898                      134 (67.7)      2236 (71.0)       0.588
  Hypercholesterolemia                          2157 (64.4)       134 (62.6)      2023 (64.6)       0.818                      146 (73.7)      2011 (63.8)       0.018
  Diabetes mellitus                             1357 (40.5)       90 (42.1)       1267 (40.4)       0.867                      76 (38.4)       1281 (40.7)       0.79
  Renal dysfunction                             574/3094 (18.6)   55/194 (28.4)   519/2900 (17.9)   \<0.001                    30/189 (15.9)   544/2905 (18.7)   0.328
  Past history of MI                            631 (18.8)        57 (26.6)       574 (18.3)        0.003                      33 (16.7)       598 (19.0)        0.419
  Past history of HF                            248 (7.4)         25 (11.7)       223 (7.1)         0.046                      10 (5.1)        238 (7.6)         0.413
  Past PCI                                      770 (23.0)        66 (30.8)       704 (22.5)        0.018                      40 (20.2)       730 (23.2)        0.607
  Past CABG                                     185 (5.5)         21 (9.8)        164 (5.2)         0.017                      7 (3.5)         178 (5.7)         0.436
  Hemodialysis                                  118 (3.5)         20 (9.3)        98 (3.1)          \<0.001                    2 (1.0)         116 (3.7)         0.048
  Cerebrovascular disease                       284 (8.5)         21 (9.8)        263 (8.4)         0.47                       15 (7.6)        269 (8.5)         0.637
  Peripheral arterial disease                   241 (7.2)         16 (7.5)        225 (7.2)         0.871                      9 (4.5)         232 (7.4)         0.136
  Chronic lung disease                          95 (2.8)          5 (2.3)         90 (2.9)          0.871                      9 (4.5)         86 (2.7)          0.319
  Presentation                                                                                                                                                   
  STEMI                                         921 (27.5)        54 (25.2)       867 (27.7)        \<0.001                    60 (30.3)       861 (27.3)        0.247
  UA/NSTEMI                                     945 (28.2)        92 (43.0)       853 (27.2)        59 (29.8)                  886 (28.1)                        
  Stable angina                                 990 (29.6)        50 (23.4)       940 (30.0)        48 (24.2)                  942 (29.9)                        
  Silent ischemia                               457 (13.6)        18 (8.4)        439 (14.0)        31 (15.7)                  426 (13.5)                        
  Other                                         35 (1.0)          0 (0)           35 (1.1)          0 (0)                      35 (1.1)                          
  Angina (applied to only elective cases) (%)                                                                                                                    
  No symptoms                                   519 (35.9)        18 (26.5)       501 (36.3)        0.167                      31 (39.2)       488 (35.7)        0.091
  CCS class                                                                                                                                                      
  I                                             213 (14.7)        11 (16.2)       202 (14.6)        8 (10.1)                   205 (15.0)                        
  II                                            500 (34.6)        22 (32.4)       478 (34.7)        25 (31.6)                  475 (34.7)                        
  III                                           153 (10.6)        13 (19.1)       140 (10.2)        15 (19.0)                  138 (10.1)                        
  IV                                            17 (1.2)          2 (2.9)         15 (1.1)          0 (0)                      17 (1.2)                          
  Unknown                                       45 (3.1)          2 (2.9)         43 (3.1)          0 (0)                      45 (3.1)                          

All values are expressed as the mean±SD or as a number with the percentage of subjects in parentheses. ACS indicates acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS class, Canadian Cardiovascular Society angina class; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐elevation myocardial infarction; UA/NSTEMI, unstable angina/non‐ST‐elevation myocardial infarction.

During the follow‐up (mean follow‐up duration, 665±147 days), a total of 214 ACS (6.4%) and 198 unplanned revascularization (5.9%) events occurred, and all‐cause mortality rate was 3.9% (N=131). Subsequent ACS events mostly consisted of UA (168 events; 78.5% of all ACS events). Propensity score matching was performed to adjust for differences in clinical variables, producing a total of 209 matched sets (patients with versus without subsequent ACS admission) and 196 matched sets (patients with versus without unplanned revascularization). The baseline demographic characteristics of the propensity‐matched cohorts are presented in Tables [3](#jah32617-tbl-0003){ref-type="table-wrap"} and [4](#jah32617-tbl-0004){ref-type="table-wrap"}. After greedy matching, baseline characteristics between matched sets were well balanced, and standardized differences were almost all below 0.1 (Figure [2](#jah32617-fig-0002){ref-type="fig"}).

###### 

Baseline Characteristics in Matched Cohort of a Subsequent ACS Readmission

  Characteristic                                Future ACS Admission   *P* Value    
  --------------------------------------------- ---------------------- ------------ -------
  Demographics                                                                      
  Male, n (%)                                   167 (79.9)             178 (85.2)   0.156
  Age, y                                        68.9±10.3              68.6±9.8     0.784
  BMI                                           24.0±3.4               24.0±3.4     0.933
  Clinical factors (%)                                                              
  Smoking, n (%)                                77 (36.8)              76 (36.4)    0.919
  Family history of CAD                         36 (17.3)              32 (15.2)    0.322
  Hypertension, n (%)                           150 (71.8)             151 (72.2)   0.913
  Hypercholesterolemia, n (%)                   133 (63.6)             153 (73.2)   0.035
  Diabetes mellitus, n (%)                      89 (42.6)              95 (45.5)    0.554
  Renal dysfunction                             23 (11.0)              25 (12.0)    0.759
  Past history of MI                            56 (26.8)              54 (25.8)    0.824
  Past history of HF                            24 (11.5)              18 (8.6)     0.329
  Past PCI                                      65 (31.1)              82 (39.2)    0.082
  Past CABG                                     21 (10.0)              12 (5.7)     0.103
  Hemodialysis                                  20 (9.6)               22 (10.5)    0.745
  Cerebrovascular disease                       21 (10.0)              16 (7.7)     0.389
  Peripheral arterial disease                   16 (7.7)               21 (10.0)    0.389
  Chronic lung disease                          5 (2.4)                6 (2.9)      0.76
  Presentation (%)                                                                  
  STEMI                                         52 (25.0)              36 (17.1)    0.001
  UA/NSTEMI                                     89 (42.8)              67 (31.9)    
  Stable angina                                 49 (23.6)              69 (32.9)    
  Asymptomatic myocardial ischemia              18 (8.7)               35 (16.7)    
  Other                                         0 (0)                  3 (1.4)      
  Angina (applied to only elective cases) (%)                                       
  No symptoms                                   43 (41.3)              18 (26.9)    0.208
  CCS class                                                                         
  I                                             11 (10.6)              11 (16.4)    
  II                                            32 (30.8)              21 (31.3)    
  III                                           16 (15.4)              13 (19.4)    
  IV                                            0 (0)                  2 (3.0)      
  Unknown                                       2 (1.9)                2 (3.0)      

All values are expressed as the mean±SD or as a number with the percentage of subjects in parentheses. ACS indicates acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS class, Canadian Cardiovascular Society angina class; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐elevation myocardial infarction; UA/NSTEMI, unstable angina/non‐ST‐elevation myocardial infarction.

###### 

Baseline Characteristics in Matched Cohort of Unplanned Revascularization

  Characteristic                                Future Revascularization Admission   *P* Value    
  --------------------------------------------- ------------------------------------ ------------ -------
  Demographics                                                                                    
  Male, n (%)                                   162 (82.7)                           166 (84.7)   0.585
  Age, y                                        68.3±10.0                            67.8±9.4     0.603
  BMI                                           24.5±3.7                             24.5±3.8     0.959
  Clinical factors (%)                                                                            
  Smoking, n (%)                                64 (32.7)                            60 (30.6)    0.664
  Family history of CAD                         28 (14.3)                            32 (16.2)    0.726
  Hypertension, n (%)                           133 (67.9)                           140 (71.4)   0.442
  Hypercholesterolemia, n (%)                   145 (74.0)                           154 (78.6)   0.285
  Diabetes mellitus, n (%)                      75 (38.3)                            82 (41.8)    0.453
  Renal dysfunction                             37 (18.9)                            58 (29.6)    0.013
  Past history of MI                            33 (16.8)                            37 (18.9)    0.598
  Past history of HF                            10 (5.1)                             4 (2.0)      0.102
  Past PCI                                      40 (20.4)                            59 (30.1)    0.027
  Past CABG                                     7 (3.6)                              4 (2.0)      0.359
  Hemodialysis                                  2 (1.0)                              7 (3.6)      0.092
  Cerebrovascular disease                       15 (7.7)                             13 (6.6)     0.695
  Peripheral arterial disease                   9 (4.6)                              16 (8.2)     0.148
  Chronic lung disease                          8 (4.1)                              10 (5.1)     0.629
  Presentation (%)                                                                                
  STEMI                                         58 (29.6)                            32 (29.6)    0.007
  UA/NSTEMI                                     59 (30.1)                            58 (29.6)    
  Stable angina                                 48 (24.5)                            71 (36.2)    
  Asymptomatic myocardial ischemia              31 (15.8)                            33 (16.8)    
  Other                                         0 (0)                                2 (1.0)      
  Angina (applied to only elective cases) (%)                                                     
  No symptoms                                   31 (39.2)                            42 (40.4)    0.307
  CCS class                                                                                       
  I                                             8 (10.1)                             12 (11.5)    
  II                                            25 (31.6)                            38 (36.5)    
  III                                           15 (19.0)                            10 (9.6)     
  IV                                            0 (0)                                0 (0)        
  Unknown                                       0 (0)                                2 (1.9)      

All values are expressed as the mean±SD or as a number with the percentage of subjects in parentheses. BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS class, Canadian Cardiovascular Society angina class; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐elevation myocardial infarction; UA/NSTEMI, unstable angina/non‐ST‐elevation myocardial infarction.

![Standardized differences of baseline characteristics between pre‐ and postmatched cohorts. After greedy matching, baseline characteristics were well balanced, and standardized differences were almost all \<0.1 in both (A) future ACS admission and (B) unplanned coronary revascularization matched cohorts. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention.](JAH3-6-e006529-g002){#jah32617-fig-0002}

Figure [3](#jah32617-fig-0003){ref-type="fig"} shows Kaplan--Meier event‐free survival curves for all‐cause death (1) in patients with and without future ACS admission and (2) in patients with and without unplanned revascularization. Whereas patients with future ACS admission had a significantly lower survival rate during the follow‐up period (*P*=0.007 by log‐rank test), the mortality of patients with unplanned revascularization was not different from those without (*P*=0.173 by log‐rank test). Cox regression analysis revealed the same trend that patients having a subsequent ACS admission were associated with worse survival (hazard ratio, 4.73; 95% confidence interval, 1.35--16.6; *P*=0.015), but patients having an unplanned revascularization were not (hazard ratio, 2.97; 95% confidence interval, 0.57--14.3; *P*=0.194).

![Kaplan--Meier survival curves for all‐cause deaths (A) in patients with and without future ACS admission and (B) in patients with and without unplanned revascularization. ACS indicates acute coronary syndrome; Revasc, revascularization.](JAH3-6-e006529-g003){#jah32617-fig-0003}

To clarify the prognostic burden within each component of ACS, we evaluated the all‐cause mortality in patients with versus without a future event stratified by UA and MI. Patients with a future MI were associated with an increased risk of all‐cause mortality compared with those without (*P*=0.013 by log‐rank test; Figure [4](#jah32617-fig-0004){ref-type="fig"}). In patients experiencing UA (161 matched sets), however, Kaplan--Meier event‐free survival curve did not show the significant difference (Figure [5](#jah32617-fig-0005){ref-type="fig"}). Furthermore, in the adjusted analysis, no association with all‐cause mortality was observed (hazard ratio, 1.39; 95% confidence interval, 0.48--4.00; *P*=0.54).

![Kaplan--Meier survival curves for all‐cause deaths in patients with a future MI readmission vs those without. MI indicates myocardial infarction.](JAH3-6-e006529-g004){#jah32617-fig-0004}

![Kaplan--Meier survival curves for all‐cause deaths in patients with and without future UA admission. UA indicates unstable angina.](JAH3-6-e006529-g005){#jah32617-fig-0005}

Discussion {#jah32617-sec-0014}
==========

In a contemporary PCI registry in Japan, the rates for ACS rehospitalization and unplanned revascularization during follow‐up period were 6.4% and 5.9%, respectively, and the all‐cause mortality rate was 3.9%. The incidence of a subsequent ACS, particularly MI, was associated with higher all‐cause mortality, but this association was less clear after unplanned coronary revascularization or UA.

It is widely known that the experience of an ACS event could have an unfavorable impact on future prognosis.[18](#jah32617-bib-0018){ref-type="ref"}, [19](#jah32617-bib-0019){ref-type="ref"} In fact, a recent report from the GRACE (Global Registry of Acute Coronary Events) demonstrated that ≈5% of patients with ACS admission had died during the indexed hospitalization, and an additional 10% of patients experienced subsequent events, including death and MI within 6 months after discharge.[19](#jah32617-bib-0019){ref-type="ref"} In accordance with this previous report, the overall ACS admission was associated with an increased risk of long‐term mortality in our study. Recent guidelines, however, do not necessarily put much emphasis on discriminating between UA and MI events from a clinical perspective (especially in the event of a non‐ST‐elevation MI),[20](#jah32617-bib-0020){ref-type="ref"} but the GRACE investigators also demonstrated minimal association between UA admission and subsequent mortality as compared with an MI admission and long‐term death.[19](#jah32617-bib-0019){ref-type="ref"} Our findings are congruent with this observation. Although UA admissions accounted for the majority of subsequent ACS admissions following index PCI (78.5%), its adverse association with all‐cause mortality was less clear in the propensity‐matched analysis. Because of the limited sample size of patients with a future MI (N=46), a fully adjusted model could not be performed. However, the crude mortality rate was higher in patients with a future MI (10.9%) as compared with a subsequent UA episode (4.8%). In addition, unadjusted survival analysis also demonstrated a higher mortality in patients with a future MI than those without (*P*=0.013 by log‐rank test; Figure [4](#jah32617-fig-0004){ref-type="fig"}). These findings indicate that MI, but not the UA component in ACS event, may largely explain the association between subsequent ACS with mortality. The specific prognostic importance of the different clinical presentations across the ACS spectrum requires further exploration.

It remains unclear whether a subsequent unplanned coronary revascularization is an appropriate component of MACE end points in the field of cardiovascular studies. For example, the FAME 2 (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2),[4](#jah32617-bib-0004){ref-type="ref"} which evaluated the role of fractional flow reserve assessment in revascularization decisions for patients with stable angina, highlighted the need for answering this question. This trial was stopped prematurely by its safety and monitoring board, because of a significant difference in a composite outcome between patients with and without revascularization. This was mainly driven by the significantly different rates for the subsequent unplanned revascularization between groups, and critics expressed concerns that the trial design failed to ensure clarification of the effect of an fractional flow reserve--guided strategy on mortality. In our study, by creating the propensity‐matched cohort to control the potential selection bias for an unplanned revascularization, we compared a subsequent mortality of patients with and without an unplanned revascularization, and the association of an unplanned revascularization and long‐term mortality was not apparent. On the basis of our findings, critiques for the premature stop of the FAME 2 attributed to a significant difference in a composite outcome between groups would be considered reasonable.

Knowing the prognostic significance of an admission for coronary revascularization may be of particular importance in a Japanese context, given that follow‐up anatomical assessment, including coronary artery angiography or coronary computed tomography angiography, is commonly performed ≈1 year after the index PCI.[21](#jah32617-bib-0021){ref-type="ref"} This practice pattern could facilitate the detection of an asymptomatic lesion and the subsequent revascularization.[22](#jah32617-bib-0022){ref-type="ref"}, [23](#jah32617-bib-0023){ref-type="ref"}, [24](#jah32617-bib-0024){ref-type="ref"} Past reports indicated that this practice is associated with an increased detection of restenosis and the implementation of revascularization.[22](#jah32617-bib-0022){ref-type="ref"}, [23](#jah32617-bib-0023){ref-type="ref"}, [24](#jah32617-bib-0024){ref-type="ref"} In addition, a recent randomized, controlled trial demonstrated that routine follow‐up angiography strategy after the initial PCI did not improve clinical outcomes, quantified as a composite of cardiovascular death, MI, and hospitalization for ACS and/or heart failure, compared with clinical follow‐up alone.[25](#jah32617-bib-0025){ref-type="ref"} However, few studies evaluated the prognostic impact of the subsequent revascularization after the initial PCI, and our study addresses this paucity of evidence. Therefore, the current findings in our study may open the further discussion about the added value of doing routine angiographic or coronary computed tomography angiography follow‐up post‐PCI, like the ones that are commonly performed within PCI treating facilities in Japan.

Limitations {#jah32617-sec-0015}
-----------

Our findings should be interpreted in the context of several potential limitations. First, despite the fact that our registry covers more than 200 clinical variables and procedure‐related factors in accordance with the National Cardiovascular Data Registry CathPCI registry in the United States, and propensity score matching was performed to control for many of these variables, the potential for unmeasured confounding remains. Second, in our registry, the follow‐up survey focused only on clinically driven events: death; ACS; heart failure; ischemic and/or hemorrhagic stroke; and bleeding. Therefore, a subsequent revascularization was retrospectively reviewed, and some revascularization events may not have been captured, especially, for cases transferred to institutions outside of the JCD‐KiCS network. Third, we were unable to obtain information on the 5% of patients that were lost to follow‐up after 2 years in our data set, and our findings may not necessarily extend to those patients. Finally, because of the small sample size and limited statistical power, caution should be exercised when interpreting our results. Even though the effects of UA and unplanned revascularization on mortality were not statistically significant, the confidence intervals surrounding the hazard ratios were wide and further replication of our findings is needed.

Future Directions {#jah32617-sec-0016}
-----------------

Our study identified several future directions with respect to research and clinical practice. From the research perspective, cardiovascular composite end points should potentially be reconsidered. Although ACS readmissions seem to be an important component of clinical end points, the roles of unplanned revascularization or UA alone as a component of trial end points warrants further study. From the clinical standpoint, given the lack of prognostic benefit from the subsequent revascularization after the index PCI, thorough discussion about the added value of performing routine angiographic assessment after the index PCI is required.

Conclusions {#jah32617-sec-0017}
===========

In Japanese patients that underwent PCI, having a subsequent ACS, particularly an MI, was associated with worse prognosis, but undergoing subsequent unplanned coronary revascularization or experiencing an episode of UA were not.
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